Valneva SE (NASDAQ:VALN) Short Interest Down 56.3% in May

Valneva SE (NASDAQ:VALN - Get Free Report) was the target of a large decline in short interest in May. As of May 31st, there was short interest totalling 2,100 shares, a decline of 56.3% from the May 15th total of 4,800 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily trading volume, of 74,200 shares, the days-to-cover ratio is presently 0.0 days.

Hedge Funds Weigh In On Valneva

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ABC Arbitrage SA bought a new position in shares of Valneva in the fourth quarter valued at $84,000. GAMMA Investing LLC bought a new position in shares of Valneva during the first quarter worth approximately $94,000. Finally, Wells Fargo & Company MN increased its holdings in shares of Valneva by 14.3% during the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after purchasing an additional 30,859 shares during the period. Institutional investors own 11.39% of the company's stock.

Analyst Ratings Changes

VALN has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $17.00 price target on shares of Valneva in a research note on Tuesday, April 15th. Guggenheim lowered their price target on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, May 8th.

Valneva Stock Performance

Shares of NASDAQ VALN traded down $0.14 during trading hours on Friday, reaching $6.01. The stock had a trading volume of 12,704 shares, compared to its average volume of 42,636. The business's fifty day moving average is $6.46 and its two-hundred day moving average is $5.94. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The company has a market cap of $511.41 million, a price-to-earnings ratio of -46.23 and a beta of 1.81. Valneva has a twelve month low of $3.62 and a twelve month high of $8.66.

Valneva (NASDAQ:VALN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.27. The company had revenue of $51.79 million for the quarter, compared to analysts' expectations of $41.80 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. As a group, research analysts expect that Valneva will post 0.13 EPS for the current year.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.